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Personalized treatment is highly desirable in multiple
sclerosis because it is an immensely heterogeneous
disease. This heterogeneity is seen in both the disease
course and the treatment responses. Currently, a
combination of clinical features and imaging
parameters in magnetic resonance imaging is used to
classify active and non-active patients and treatment
responders and non-responders. Although this
classification works on a group level, individual
patients often behave differently from the group.
Therefore additional biomarkers are needed to
provide better indicators for prognosis and treatment
response. Basic and clinical research have discovered
different promising targets. It is now essential to verify
the utility and accuracy of these markers in large,
prospectively sampled patient cohorts.




Multiple sclerosis (MS) is a chronic autoimmune disease
of the central nervous system. Because it hits patients
early during life it has a major impact on a large part of
their lives, and imposes a considerable economic burden.
Current treatments for MS mainly target inflammatory
processes, and there has been scant progress in treatments
that enhance neuronal or glial regeneration. Therefore the
current treatment strategy is to start treatment early to
prevent neurodegeneration from the beginning. However,
different problems arise when patients are treated after the
first sign of the disease. First, does the patient need treat-
ment at all, because he or she may have a benign disease
course? Second, to which of the current baseline therapies
will the patient respond best? Third, does the patient need
an induction therapy? Fourth, is the patient at an
increased risk for serious side effects?
Data from clinical trials provide information about effi-
cacy and safety on a group level. However, it is obvious
that treatment decisions in clinical practice must be made
on an individual basis. This requires a personalized medi-
cine approach. Biomarkers that could predict disease
course, treatment response, and risk of side effects would
be highly appreciated. Despite extensive research over the
last years, few biomarkers have made their way into clini-
cal practice. This mini review aims to summarize the state
of current biomarker development in MS and promising
new approaches.
Predicting disease activity in multiple sclerosis
MS is a highly heterogeneous disease. This is probably not
only true for the etiology, pathological features and auto-
antigenic targets but also for the disease course and
response to treatment. Data from natural history cohorts
show a broad spectrum of disease severities. The disease
course is benign in 10% to 15% of patients and they do
not need an assistive device for walking even after 20 years
of MS [1]. On the other end of the spectrum, there are ful-
minant courses of MS that lead to severe disability within
a few years. This heterogeneity of disease severity has
obvious consequences for treatment decisions. In patients
with a more aggressive disease, there is a need for early
and aggressive treatment. Although this aggressive treat-
ment poses some risks, these risks would be accepted by
the patient and treating physician knowing that the bene-
fits in this specific patient outweigh the potential risks.
Can we predict the disease course? There seem to be
some clinical indicators that point to a worse disease
course, such as high relapse rate during the first two to
three years, bad recovery from relapses, and motor symp-
toms early during disease [2-4] (although these predictors
have been disputed by others [5,6]). In addition, paraclini-
cal tests such as high lesion load in magnetic resonance
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imaging (MRI), lipid-specific IgM oligoclonal bands and
certain electrophysiological parameters hint at a more
active disease (Table 1) [7-9]. However, while all these
factors work fine on a group level, their predictive power
in individual patients is low. Nevertheless, MRI is exten-
sively used in clinical practice as a surrogate marker for
the burden and activity of disease [10]. It can be expected
that compound MRI measures that combine classical
sequences like T2 and contrast enhanced T1 with more
sophisticated measures like diffusion tensor imaging, dou-
ble inversion recovery and magnetization transfer ratio will
enhance the predictive power of MRI [11]. These techni-
ques will allow for the detection of grey matter lesions that
occur early during the disease course and that seem to cor-
relate better with disability than white matter lesions that
are detected with the standard T2-weighed imaging [12].
How to pick the right medication for the right patient?
To date, choosing the right first-line therapy is based on
guessing rather than knowing. On the one hand, one has
to consider the activeness and severity of the disease
when choosing a therapy. On the other hand, one has to
take into account that no treatment has a responder rate
of 100%. If a patient is placed on a treatment that does
not work perfectly, this patient will lose precious time
and will still have the risks of the treatment. In addition,
society will have costs without benefit. Therefore there is
an immense need to establish biomarkers that can pre-
dict treatment responses. So far, the response to a treat-
ment is judged by counting clinical relapses, disability
progression, and new lesions in MRI after one year of
treatment [13]. Established biomarkers that are corre-
lated with treatment responses include neutralizing
antibodies against IFNs and natalizumab (Table 1)
[14,15]. Genetic markers have not proven to be of use in
predicting treatment response, so far. Recent studies on
transcriptional profiles (both mRNA as well as miRNA)
might reveal IFN response markers but this has to be
reproduced in further longitudinal patient cohorts [16].
Another class of biomarkers is defined by the detec-
tion of pathologic immune responses, primarily antibody
responses, against putative autoantigens [17]. These
have been established as biomarkers in other neuroim-
munological diseases such as myasthenia (antibodies
against acetylcholine receptor) and paraneoplastic disor-
ders (anti-Hu, anti-Yo and so on). In demyelinating dis-
eases of the central nervous system, aquaporin 4
(AQP4) and myelin oligodendrocyte glycoprotein
(MOG) have emerged as interesting antibody targets.
Antibodies against AQP4 are associated with the clinical
spectrum of neuromyelitis optica [18]. Because neuro-
myelitis optica seems to have a more aggressive course
than general MS and seems to respond better to classi-
cal immunosuppression than to immunomodulation,
detection of AQP4 antibodies helps to classify patients
and aids in treatment decisions. Antibody responses
against MOG are mainly found in pediatric demyelinat-
ing diseases like acute disseminated encephalomyelitis
and pediatric MS [19]. MOG antibodies might help in
differentiating between viral and autoimmune encephali-
tis [20]. Monophasic acute disseminated encephalomye-
litis and pediatric MS might also be separated by MOG
antibodies because these antibodies tend to persist
longer in pediatric MS [19]. However, more longitudinal
data are needed to corroborate this finding. If it is true,
persisting anti-MOG antibodies would aid in guiding
Table 1 Summary of established and potential biomarkers for diagnosis, prognosis, and treatment of multiple
sclerosis.
Established biomarkers Diagnosis Prognosis Treatment response/side effects
Cerebral spinal fluid-specific oligoclonal bands + (+) -
Intrathecal immunoglobulin production + (+) -
Intrathecal anti-viral immunoglobulin production + - -
Magnetic resonance imaging + (+) (+)
Neutralizing antibodies against beta-interferon - - (+)
Neutralizing antibodies against natalizumab - - +
Antibodies against JC virus - - +
Aquaporin 4 antibodies + (+) (+)
Potential biomarkers
CD56 bright natural killer cells - - (+)
Cytokines/chemokines - - (+)
Myelin oligodendrocyte glycoprotein antibodies (+) - -
Intrathecal/oligoclonal immunoglobulin M production - (+) -
Transcriptomics - - (+)
Genetics (+) (+) (+)
+ valid biomarker that is used in clinical practice; (+) there is experimental and clinical evidence for this biomarker, but the need for more clinical data; - there is
no clear evidence.
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prophylactic treatment regimens. The role of MOG anti-
bodies in adult MS is still speculative. More research is
needed to clarify if MOG antibodies can be used for
prognosis or classification of adult MS patients. A very
recent discovery is the increased humoral immune
response against KIR4.1 that was found in different
cohorts of patients with MS compared with different
control cohorts [21]. KIR4.1 is a rectifying potassium
channel expressed by astrocytes and oligodendrocytes.
Injection of KIR4.1 specific IgG (derived from MS sera)
into the cisterna magna of mice caused pathological
changes like complement deposition and loss of KIR4.1
antigen. As with MOG, it remains to be seen if the
immune response against KIR4.1 will be useful as a bio-
marker for diagnosis, prognosis or treatment responses.
Another novel biomarker that may predict treatment
responses early during therapy was discovered during clin-
ical development of daclizumab, a monoclonal anti-CD25
antibody. It was shown that blocking the high-affinity IL-2
receptor (CD25) by daclizumab led to the expansion of a
subtype of NK cells that show a high expression of CD56.
This cell type seems to have immunoregulatory functions
[22]. Expansion of CD56bright NK T-cells correlated with
decreased MRI activity during daclizumab therapy in a
phase 2 trial and may therefore indicate a patient popula-
tion that preferentially responds to this treatment [23].
Despite these promising new avenues of research, we are
currently left with clinical markers of treatment responses.
Can we predict the risk of serious side effects?
When using immunosuppressive or immunomodulatory
treatment, we are often confronted with serious side
effects such as increased risk for infections. These risks
often increase with the effectiveness of the treatments.
A prominent example is the treatment with natalizu-
mab, a monoclonal antibody against an integrin that
inhibits migration of lymphocytes into the brain. This
treatment shows an impressive reduction of relapses and
disease activity in MRI [24]. The major drawback of this
treatment is, however, the increased risk for a progres-
sive multifocal leukoencephalopathy (PML) [25]. A care-
ful review of PML cases in a post-marketing safety
program revealed that a longer duration of therapy and
previous immunosuppressive treatment are correlated
with an increased risk of PML. As far as we know, PML
is a reactivation of a preexisting latent infection with JC
virus. A specific ELISA for the causative JC virus was
developed that indicates if a patient harbors latent JC
virus [26]. Using these three parameters (treatment
duration, previous immunosuppressive treatment, JC
virus antibody status), a risk stratification algorithm has
been established that can be used in clinical practice to
counsel patients that are on current natalizumab treat-
ment or that are suited to go on the treatment [25].
Another biomarker that could predict autoimmune
side effects of a treatment with alemtuzumab (monoclo-
nal antibody against CD52 that depletes lymphocytes
and monocytes) has been identified in early clinical stu-
dies. A surprising finding was made during the early
clinical development of alemtuzumab: the occurrence of
autoimmune thrombocytopenia and thyroid disease [27].
The pretreatment levels of IL-21 in serum correlated
with the later development of autoimmune reactions
[28]. Obviously, more prospective data are needed to
confirm the value of this test in clinical practice.
The genetic background of a patient could also be
used as a personalized biomarker. With the advent of
high-throughput genetic screening approaches, genetic
data are available in high quality and at ever decreasing
costs. Some health authorities already demand genetic
testing for certain human leukocyte antigen (HLA) hap-
lotypes to predict the risk of serious cutaneous adverse
effects of carbamazepine treatment [29]. In MS, an
increasing number of genetic polymorphisms have been
correlated with the disease [30] but so far their power
to aid in diagnosing MS is low [31]. A large number of
genes (including GSTM, IL1B, PD-1, CCR5, OPN, IL4,
HLA-DRB1*1501, CD24, ESR1, CD59, CNTF, CRYAB,
IFNg, MEFV, APOE, TGFB1) have been associated with
certain MS phenotypes but these correlations were often
controversial [32].
Research on the pharmacogenomics of MS is increas-
ing but a useful biomarker for clinical practice has so far
not emerged [33]. Nevertheless, a recent study analyzing
the functional consequences of a TNF receptor 1 poly-
morphism linked to MS shed light on possible reasons
why a TNFa blockade failed as therapy in MS when they
have been effective for other autoimmune diseases
[34,35]. Gregory and colleagues [35] showed that this
polymorphism leads to a novel soluble TNF receptor that
can block TNFa, suggesting that a TNFa blockade in MS
contributes to its pathogenesis rather than protecting
from it. This study suggests that the functional analysis
of genetic variants might help to predict autoimmune
side effects related to specific immune pathways.
Future directions and conclusions
The treatment armamentarium of MS has increased tre-
mendously over the last few years and more treatments
are close to registration. Although a final cure for MS is
still missing, MS will be manageable in most patients with
these treatments. The most important challenge regarding
these therapeutic interventions will be to tailor the therapy
to the needs of the patients and the aggressiveness of the
disease. This asks for the development of biomarkers,
either clinical, genetic, imaging or immunological, that
allow for a better stratification of patients. An important
prerequisite of biomarker development is the availability
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of longitudinal patient cohorts that are followed up over
years. These cohorts could provide prospectively collected
clinical information as well as genetic, imaging and immu-
nological data. Many biomarkers have been proposed in
clinical research. To finally bring them to clinical practice
needs academic and industry co-operation. This joint
effort will bring us one step closer from the hope to the
reality of personalized medicine in MS.
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